The U.S. Department of Health and Human Services published a Request for Information in the Federal Register on June 10, 2026, inviting public comment on which research, programs, and policies have been most successful in treating addiction, improving mental health outcomes, and supporting long-term recovery. The comment period runs through July 5, 2026, and is framed as part of HHS Secretary Robert F. Kennedy Jr.’s broader initiative, the administration has called the “Great American Recovery.”
The RFI arrives at a sobering moment for American public health. Opioid overdose deaths have remained above 70,000 annually since 2017 and exceeded 80,000 in 2024, making drug overdose one of the leading causes of death among Americans under age 55. Fentanyl and other synthetic opioids now account for the vast majority of these deaths. The toll extends far beyond mortality statistics — addiction devastates families, communities, workforce participation, and the children of people with substance use disorders.
The notice explicitly invites input from patients, people with lived experience of addiction and recovery, healthcare providers, community organizations, and researchers. The framing reflects a genuine uncertainty about the best path forward at the federal level — and, depending on how the administration responds to the comments received, could foreshadow significant shifts in federal drug and mental health policy.
What the Science Says About Addiction Treatment
The research base for addiction treatment has expanded substantially over the past two decades, and several evidence-based approaches have demonstrated consistent results. Medication-assisted treatment (MAT) for opioid use disorder — using buprenorphine (Suboxone), methadone, or naltrexone (Vivitrol) — remains the most extensively studied and most effective approach for reducing overdose deaths and helping patients maintain recovery. A landmark 2023 study in the New England Journal of Medicine found that patients receiving buprenorphine had significantly lower rates of overdose death than those who did not.
Despite this evidence, access to MAT remains severely limited. Fewer than 20 percent of people with opioid use disorder receive it, partly due to stigma, provider reluctance to prescribe, geographic disparities, and insurance barriers. Advocacy groups and harm reduction organizations have consistently pushed for more accessible prescribing, expanded availability in emergency departments, and removal of administrative barriers to buprenorphine.
Residential treatment, peer support specialists, contingency management (which uses positive reinforcement to promote drug-free behavior and is especially effective for stimulant use disorders), and community-based case management have all shown benefit in specific contexts. Mental health co-treatment is also increasingly recognized as essential, given that the majority of people with substance use disorders have co-occurring anxiety, depression, trauma, or other psychiatric conditions.
Harm reduction strategies — needle exchange programs, naloxone distribution, fentanyl test strips, supervised consumption sites — have a strong evidence base for reducing overdose deaths and HIV transmission, though they remain politically controversial and are not universally available.
What Advocates Want the Administration to Hear
Public health advocates are watching this comment process closely. Many are hoping the RFI signals a genuine commitment to expanding evidence-based treatment access rather than a pivot toward approaches that lack a strong scientific foundation. Questions about how the Kennedy-led HHS will address the scientific consensus on MAT, harm reduction, and the role of abstinence-only models will shape the federal response for years.
The comment process is open to all members of the public at federalregister.gov. Comments submitted by the July 5, 2026 deadline will inform HHS policy development.
Frequently Asked Questions
Q: What is the HHS asking for in this public comment request?
A: HHS is seeking input on which addiction treatment programs, policies, and research approaches have been most successful — to guide future federal policy and funding priorities.
Q: What are the most effective treatments for opioid use disorder?
A: Medication-assisted treatment (MAT) using buprenorphine, methadone, or naltrexone has the strongest evidence base. Combined with counseling and support services, MAT significantly reduces overdose deaths.
Q: How many Americans die of opioid overdoses each year?
A: Opioid overdose deaths exceeded 80,000 in 2024. Fentanyl and synthetic opioids now account for the vast majority of these deaths.
Q: How can I submit comments to the HHS RFI?
A: Comments can be submitted at federalregister.gov by the July 5, 2026 deadline.
Q: What is harm reduction and why is it controversial?
A: Harm reduction includes strategies like naloxone distribution, needle exchanges, and fentanyl test strips that reduce the risks of drug use without requiring abstinence. Evidence strongly supports their effectiveness, but they remain politically controversial in some settings.
